Efficacité du gefitinib (Iressa) pour le traitement d’un carcinome bronchioloalvéolaire inopérable

作者: S. Bayle , R. Descourt , S. Gouva , C. Daniel , G. Robinet

DOI: 10.1016/S0761-8425(04)71248-6

关键词:

摘要: Resume Introduction Le carcinome bronchioloalveolaire est une tumeur bronchique rare. seul traitement curatif actuellement la chirurgie et les formes inoperables sont souvent resistantes a chimiotherapie radiotherapie. Cas clinique Une patiente de 76 ans ete operee d’un (BAC) classe pT2N0M0. Trois mois plus tard, presentait toux dyspnee le bilan realise montrait recidive maladie type d’envahissement pulmonaire bilateral. Elle recu alors deux lignes chimiotherapies successives permettant au mieux stabilisation maladie. La decision therapeutique etait surveillance simple. Six qu’il existait progression des lesions maniere bilaterale, un par gefitinib dose 250 mg/jour initie, amelioration rapide symptomatologie clinique. radiographie scanner thoracique montraient aspect reponse partielle qui se maintient, an apres debut du traitement. Conclusion Cette observation rapporte l’interet dans BAC pour lesquels il n’existe ce jour aucune efficace.

参考文章(11)
Nai-San Wang, Chi-Der Chiang, Chih-Mei Huang, Gee-Chen Chang, Tsung-Ying Yang, Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients. Journal of the Formosan Medical Association. ,vol. 102, pp. 407- 411 ,(2003)
LH Sobin, WD Travis, TV Colby, B Corrin, Y Shimosato, E Brambilla, Histological Typing of Lung and Pleural Tumours ,(1999)
Motoshi Takao, Kentarou Inoue, Fumiaki Watanabe, Koji Onoda, Takatsugu Shimono, Hideto Shimpo, Isao Yada, Successful treatment of persistent bronchorrhea by gefitinib in a case with Recurrent Bronchioloalveolar Carcinoma: a case report World Journal of Surgical Oncology. ,vol. 1, pp. 8- 8 ,(2003) , 10.1186/1477-7819-1-8
Jyoti D. Patel, Vincent A. Miller, Mark G. Kris, Neelam T. Shah, Barbara Pizzo, Leslie Tyson, Maureen Zakowski, Natalie Memoli, Robert Heelan, David H. Johnson, O-188 Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinoma Lung Cancer. ,vol. 41, ,(2003) , 10.1016/S0169-5002(03)91846-0
Marie Wislez, Marie-Ange Massiani, Bernard Milleron, Abdelkader Souidi, Marie-France Carette, Martine Antoine, Jacques Cadranel, Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest. ,vol. 123, pp. 1868- 1877 ,(2003) , 10.1378/CHEST.123.6.1868
Howard L. West, Wilbur A. Franklin, Paul Gumerlock, Ralph B. Vance, Derick H.M. Lau, Kari Chansky, John Crowley, Jason McCoy, David R. Gandara, O-187 ZD1839 (iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG SO126 Lung Cancer. ,vol. 41, ,(2003) , 10.1016/S0169-5002(03)91845-9
David H. Johnson, Carlos L. Arteaga, Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial? Journal of Clinical Oncology. ,vol. 21, pp. 2227- 2229 ,(2003) , 10.1200/JCO.2003.04.001
Seiji Yano, Takanori Kanematsu, Toyokazu Miki, Yoshinori Aono, Masahiko Azuma, Akihiko Yamamoto, Hisanori Uehara, Saburo Sone, A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (“Iressa”1 Cancer Science. ,vol. 94, pp. 453- 458 ,(2003) , 10.1111/J.1349-7006.2003.TB01464.X
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai, Kazumasa Noda, Ichiro Takata, Egbert Smit, Steven Averbuch, Angela Macleod, Andrea Feyereislova, Rui-Ping Dong, José Baselga, None, Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 21, pp. 2237- 2246 ,(2003) , 10.1200/JCO.2003.10.038